Arcus Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RCUS New York 2836 arcusbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcus Biosciences, Inc.

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy - Sep 22nd, 2026 6:30 am
Arcus Biosciences Announces New Employment Inducement Grants - Sep 9th, 2026 2:35 pm
Arcus Biosciences to Participate in Three Upcoming Investor Conferences - Aug 26th, 2026 2:05 pm
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Aug 13th, 2026 6:03 pm
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript - Aug 12th, 2026 7:14 pm
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says - Aug 10th, 2026 10:01 am
Arcus Biosciences Q2 Earnings Call Highlights - Aug 8th, 2026 9:03 pm
Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism - Aug 7th, 2026 11:10 pm
Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary - Aug 6th, 2026 6:30 am
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates - Aug 5th, 2026 6:35 pm
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update - Aug 5th, 2026 2:05 pm
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus - Jul 24th, 2026 7:10 am
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... - Jul 23rd, 2026 11:01 pm
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study - Jul 23rd, 2026 8:31 am